Human BioSystems Confirms Earlier Organ Preservation Survival Test Results - 500 Beiträge pro Seite

[wayne99]

Press Release Source: Human BioSystems

Breaking News: Human BioSystems Confirms Earlier Organ Preservation Survival Test Results-Now Seeks Strategic Partner
Monday December 19, 7:00 am ET

PALO ALTO, Calif.--(BUSINESS WIRE)--Dec. 19, 2005--Human BioSystems (OTCBB:HBSC - News), developer of preservation platforms for organs and other biomaterials, announces today that it has confirmed the results announced in the press release of October 19, 2005 by doubling the total sample size used in the initial survival study of animals with transplanted kidneys preserved using the Company`s HBS Above Zero Organ Preservation (HBS-AZ) Solution. In comparison to kidneys stored in a solution presently considered the medical gold standard in Europe (and quickly gaining acceptance in the U.S.) named the "HTK" solution, the HBS-AZ solution exhibited significantly better results.

ADVERTISEMENT
"In the cumulative results of the survival studies, we continued to have 80% of the rats with kidneys preserved in the HBS-AZ solution survive for more than seven days, whereas only 10% of the same number of rats with kidneys preserved in the HTK solution survived more than seven days," said Dr. Fernando Lopez, HBS Senior Research Scientist.

"There is a statistical significance to the results obtained and our HBS-AZ preservation solution is significantly better than the HTK solution in this study," said Dr. Luis Toledo, HBS Chief Medical Officer.

Dr. David Winter, HBS President, stated that "there are over 40,000 organ transplants performed in the world each year and more than 90,000 people are on the waiting list in the U.S. alone that need a new organ, according to UNOS (United Network for Organ Sharing). Because of the acute shortage of available donor organs, improvements in preservation time and quality of the preserved organ should serve to further optimize the available organ pool by increasing the percentage of successful transplants."

Dr. Winter further stated that "We are now actively seeking a strategic partner that would participate with HBS to obtain FDA approval and to market our HBS-AZ preservation solution to hospitals and organ procurement organizations throughout the world."

HBS is headquartered in Palo Alto, California with research facilities in Michigan.

Certain statements contained herein are "forward-looking`` statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company`s products, if required, failure to develop a product based on the Company`s technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission

Human BioSystems (OTC Bulletin Board:HBSC - News)


Contact:

Human BioSystems
Harry Masuda
CEO
[phone]
[e-mail]
OR
YES INTERNATIONAL
Rich Kaiser
Investor Relations
[phone]
[e-mail]

Source: Human BioSystems

[starbull]

Hallo,
diese News wird in USA den Kurs rapide steigen lassen. Noch könnt Ihr bei uns günstig rein! Aufwachen!!

[xTRADERx]

Ich hoff`s mal.

Daumen drücken!

Greetz

xTRADERx

[wayne99]

[posting]19.337.093 von xTRADERx am 19.12.05 15:19:46[/posting]USA RT:

HBSC.OB 9:39am 0.46 +0.02 +4.55% 0.45 0.494 17,000

zwar im Plus aber noch wenig Umsatz

[wayne99]

RT:
HBSC.OB 9:59am 0.48 +0.04 +9.09% 0.45 0.493 22,000